Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Odile Filhol

Showing results (1-10 of 66) with videos related to

Pageof 7
Sort By:
Science Signaling|May 12, 2011
Protein kinases curb cell deathOdile Filhol, Claude Cochet
Bulletin Du Cancer|April 10, 2002
[Protein kinase CK2 and cancer: further clues are accumulating]Odile Filhol, Claude Cochet
International Journal of Cancer|September 22, 2024
New players in the landscape of renal cell carcinoma bone metastasis and therapeutic opportunitiesBeatrice Cesana, Claude Cochet, Odile Filhol
EMBO Reports|April 3, 2004
Protein kinase CK2: a new view of an old molecular complexOdile Filhol, Jean-Louis Martiel, Claude Cochet
Cellular and Molecular Life Sciences : CMLS|May 21, 2015
Protein kinase CK2 in breast cancer: the CK2β regulatory subunit takes center stage in epithelial plasticityOdile Filhol, Sofia Giacosa, Yann Wallez, et al.
Annals of the New York Academy of Sciences|December 18, 2002
Dynamic localization/association of protein kinase CK2 subunits in living cells: a role in its cellular regulation?Véronique Martel, Odile Filhol, Arsenio Nueda, et al.
Biological Chemistry|March 30, 2007
HIRIP3 is a nuclear phosphoprotein interacting with and phosphorylated by the serine-threonine kinase CK2Nadine Assrir, Odile Filhol, Frédéric Galisson, et al.
Medecine Sciences : M/S|March 14, 2007
[Therapeutic agents targetting protein-protein interactions: myth or reality?]Béatrice Laudet, Renaud Prudent, Odile Filhol, et al.
Frontiers in Oncology|August 12, 2022
Editorial: <i>in vitro</i> and <i>in vivo</i> non-clinical models of kidney cancersValérian Dormoy, Odile Filhol, Carole Sourbier, et al.
Molecular and Cellular Biochemistry|July 1, 2008
Protein kinase CK2 and cell polarityAlexandre Deshière, Nathalie Theis-Febvre, Véronique Martel, et al.
Pageof 7

Showing results (1-10 of 66) with videos related to

Sort By:
Pageof 7
Science Signaling|May 12, 2011
Protein kinases curb cell deathOdile Filhol, Claude Cochet
Bulletin Du Cancer|April 10, 2002
[Protein kinase CK2 and cancer: further clues are accumulating]Odile Filhol, Claude Cochet
International Journal of Cancer|September 22, 2024
New players in the landscape of renal cell carcinoma bone metastasis and therapeutic opportunitiesBeatrice Cesana, Claude Cochet, Odile Filhol
EMBO Reports|April 3, 2004
Protein kinase CK2: a new view of an old molecular complexOdile Filhol, Jean-Louis Martiel, Claude Cochet
Cellular and Molecular Life Sciences : CMLS|May 21, 2015
Protein kinase CK2 in breast cancer: the CK2β regulatory subunit takes center stage in epithelial plasticityOdile Filhol, Sofia Giacosa, Yann Wallez, et al.
Annals of the New York Academy of Sciences|December 18, 2002
Dynamic localization/association of protein kinase CK2 subunits in living cells: a role in its cellular regulation?Véronique Martel, Odile Filhol, Arsenio Nueda, et al.
Biological Chemistry|March 30, 2007
HIRIP3 is a nuclear phosphoprotein interacting with and phosphorylated by the serine-threonine kinase CK2Nadine Assrir, Odile Filhol, Frédéric Galisson, et al.
Medecine Sciences : M/S|March 14, 2007
[Therapeutic agents targetting protein-protein interactions: myth or reality?]Béatrice Laudet, Renaud Prudent, Odile Filhol, et al.
Frontiers in Oncology|August 12, 2022
Editorial: <i>in vitro</i> and <i>in vivo</i> non-clinical models of kidney cancersValérian Dormoy, Odile Filhol, Carole Sourbier, et al.
Molecular and Cellular Biochemistry|July 1, 2008
Protein kinase CK2 and cell polarityAlexandre Deshière, Nathalie Theis-Febvre, Véronique Martel, et al.
Pageof 7